Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Selumetinib Formulations
NCT03649165Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selumetinib in neurofibromatosis type 1 (NF1) (4 arms), sponsored by AstraZeneca. Primary endpoints: Dose normalized area under plasma concentration-time curve from time zero to infinity, Dose normalized area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 2 more. Started Sep 2018; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT03649165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649165.